HCS Pharma (HCS) STO Rating, Reviews and Details

Apr 8, 2022

Jun 8, 2022

100% completed

$209 720 767

28% goal completed

734 022 685.00 USD

past

1 HCS

=

500 USD

Token Details

Ticker

HCS

Total supply

€ 7 million

Token Distribution

European Digital Asset Exchange | https://www.edsx.ch/projects/hcs-pharma

Accepted Currencies

BTC, CHF, EUR, USDT, DOLLAR

Min Contribution

500

TOKEN

Company Details

Registered Company Name

HCS Pharma SAS

Registered Country

France

Company Founded

Jan 1, 2014

Bonus Structure

20% discount offered on final share price

Additional Details

Platform

eos

About HCS Pharma

HCS Pharma is a biotechnology company focused on in vitro R&D, specializing in high content (HCA) and high throughput (HCS) cell imaging screening. HCS Pharma sells products based on BIOMIMESYS® technology, and develops its own 3D cellular models in its proprietary BIOMIMESYS® extracellular matrix. BIOMIMESYS® 3D culture technology faithfully reproduces the natural microenvironment of cells in 3D, to ensure more predictive results from in vitro studies, to reduce the time and cost of R&D, and animal testing in pharmaceutical, nutraceutical and cosmetic companies. BIOMIMESYS® technology is also requested to be used in cell therapy and regenerative medicine, allowing HCS Pharma to become the leader in all biotechnology industries in the next 5 years.

Features

BIOMIMESYS® is a unique groundbreaking 3D cell culture technology which associates the behavior of a solid scaffold and of a hydrogel which provide a cell culture microenvironment reproducing all aspects of human tissues, including matrix architecture, cellular organization, cell-cell and cell-matrix interactions.

Depending on the organ, extracellular matrix components may vary as well their proportions, allowing a more or less dense and compact cellular environment (different Elastic Modulus, porosity).

BIOMIMESYS® matrices are made of Hyaluronic Acid (HA), the main glycosaminoglycan (GAG) of the ECM, collagens and adhesion proteins. Our patented manufacturing process allow preserving the natural properties of HA and therefore synthesizing proprietary Hydroscaffold™.

Technical Info

HCS Pharma owns 2 cell culture labs and one automation lab equipped with a robotic platform named HAPIx, including 2 confocal HCS systems, ImageXpress micro confocal systems from Molecular Devices, and a ImageXpress micro XLS also from Molecular Devices and a chemical lab for BIOMIMESYS® production.

HCS Pharma Roadmap

18 months

- 6 months: Development of a sales force in the different countries in Europe.

- 1 year: New production line set up + Development of a technical support center in Taiwan + fundraising and/or IPO project.

- 18 months: Presence in the US.

10 Years

- In 3 years, from patient cells, we will be able to recreate small diseased organs to test molecules and find the most suitable therapy for personalized medicine.

- In 5 years, we will be able to find much more effective clinical drug candidates and therefore ultimately treat patients with cancer, Parkinson's disease, or Alzheimer's.

- In 10 years, we will be able to recreate complete organs for organ transplantation. And from animal cells, we will be able to recreate muscle and therefore cultured meat.

HCS Pharma Team

Verified 25%

Attention. There is a risk that unverified members are not actually members of the team

Nathalie Maubon

CEO

verified

Elodie Vandenhaute

Project Manager

Zied Souguir

Biomaterial Department Manager

Gregory Maubon

Chief Development Officer and IA Project Leader

Advisors

Verified 100%

Mauro Andriotto

Advisor

verified

HCS Pharma Interviews

Mauro Andriotto

As a team member, сan you tell us about your role in the ICO project?

I am the CEO of the European Digital Assets Exchange where HCS Pharma is listed on the primary market.

What do you think about idea?

It's an amazing company selected by the European Commission between the most 50 most disruptive biotech in Europe and there is the plan to list the company on the Frankfurt Stock Exchange by the end of the year.

Nathalie Maubon

As a team member, сan you tell us about your role in the ICO project?

We have decided to go public before the end of the year by a Reverse Take Over (RTO) with a pre-IPO fund-raising such as STO. This STO in pre-IPO will give the possibility to crypto investors to be onboarded.

What do you think about idea?

This STO coupled with the STO makes it possible to rally virtual currency investors with the traditional market.